Evidence map›Paper›PMID 29621870›Full record

ArticleRadiation oncology journal2018

Preoperative short course radiotherapy with concurrent and consolidation chemotherapies followed by delayed surgery in locally advanced rectal cancer: preliminary results.

Mahdi Aghili, Sarvazad Sotoudeh, Reza Ghalehtaki, Mohammad Babaei, Borna Farazmand, Mohammad-Sadegh Fazeli, Amir Keshvari, Peiman Haddad, Farshid Farhan

Open access · diamondAbstract read
In one paragraph

Article in Radiation oncology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Radiotherapy and COVID-19: Practical recommendations from iran.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mahdi AghiliRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Sarvazad SotoudehRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Reza GhalehtakiRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad BabaeiRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Borna FarazmandRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad-Sadegh FazeliColorectal Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Amir KeshvariColorectal Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Peiman HaddadRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Farshid FarhanRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRImam Khomeini Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to assess complications and outcomes of a new approach, that is, combining short course radiotherapy (SRT), concurrent and consolidative chemotherapies, and delayed surgery. MATERIALS AND

methodsIn this single arm phase II prospective clinical trial, patients with T3-4 or N+ M0 rectal adenocarcinoma were enrolled. Patients who received induction chemotherapy or previous pelvic radiotherapy were excluded. Study protocol consisted of three-dimensional conformal SRT (25 Gy in 5 fractions in 1 week) with concurrent and consolidation chemotherapies including capecitabine and oxaliplatin. Total mesorectal excision was done at least 8 weeks after the last fraction of radiotherapy. Primary outcome was complete pathologic response and secondary outcomes were treatment related complications.

resultsThirty-three patients completed the planned preoperative chemoradiation and 26 of them underwent surgery (24 low anterior resection and 2 abdominoperineal resection). Acute proctitis grades 2 and 3 were seen in 11 (33.3%) and 7 (21.2%) patients, respectively. There were no grades 3 and 4 subacute hematologic and non-hematologic (genitourinary and peripheral neuropathy) toxicities and perioperative morbidities such as anastomose leakage. Grade 2 or higher late toxicities were observed among 29.6% of the patients. Complete pathologic response was achieved in 8 (30.8%) patients who underwent surgery. The 3-year overall survival and local control rates were 65% and 94%, respectively.

conclusionThis study showed that SRT combined with concurrent and consolidation chemotherapies followed by delayed surgery is not only feasible and tolerable without significant toxicity but also, associated with promising complete pathologic response rates.

Indexed as

Anticancer drug combinationCombined modality therapyConformal radiotherapyConsolidation chemotherapyIranRectal cancerXELOX

Identifiers

PMID29621870
PMCPMC5903358
OpenAlexW2794935873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.